Artfun+ is used by one of the world’s top 10 best Hospitals
In a remarkable stride towards advancing medical diagnostics and treatment, Pitié-Salpêtrière Hospital, a beacon of excellence in the healthcare realm and consistently ranked among the world’s top 8 best hospitals 2024, has chosen to harness the power of Artfun+, a cutting-edge technology. Developed by Imageens a French leading startup in medical technology, Artfun+ is set to revolutionize the measurement of imaging biomarkers for predicting and detecting the earliest signs of cardiovascular diseases. This move further amplifies the hospital’s already esteemed reputation for medical innovation, propelling it to even greater heights.”
We had the privilege to sit with Dr. Alban Redheuil, Head of the Cardiovascular Radiology Department at Pitié-Salpêtrière Hospital, to discuss the potential of ArtFun+, where he sheds light on the innovative aspects that make ArtFun+ stand out and its transformative impact on patient care.
Question 1: The Versatile Applications of ArtFun+
Dr. Alban Redheuil expresses his enthusiasm about the integration of ArtFun+ at Pitié-Salpêtrière Hospital. “I am thrilled that we have introduced this solution at Pitié-Salpêtrière, which I find particularly innovative on two different fronts.”
He goes on to elucidate the hospital’s dual objectives: “Today, our primary goals are to visualize blood flow non-invasively, particularly within the heart and vessels using MRI, and to accurately quantify both negative and positive flows. ArtFun+ excels in fulfilling these needs. The first vital application is the visualization and quantification of blood flow in major vessels, such as the aorta. The second application involves measuring the elasticity of vessels, particularly within the aorta. This demands precise measurement of vessel deformation during the cardiac cycle, for which ArtFun+ provides a specialized tool.”
Question 2: Selecting ArtFun+ for Its Unparalleled Quality and Integration
When asked about the decision to opt for ArtFun+ over its competitors, Dr. Alban Redheuil emphasizes the technology’s distinctive qualities: “The primary reason is its unmatched quality, robustness, and extensive validation.”
He elaborates, “Accurate measurement of blood flow and deformation relies on robust and reproducible vessel segmentation. ArtFun+ boasts a significant advantage in this regard, originating from Sorbonne University’s esteemed academic research and subsequently transferred to Imageens. Furthermore, ArtFun+ seamlessly integrates into our workflow routine, with the added benefit of potential AI-driven automation. This combination of speed, accuracy, and ease of integration makes ArtFun+ an invaluable asset.”
Question 3: Advancing Patient Care Through Precise Diagnostics and Prognostics
Dr. Alban Redheuil sheds light on the diverse spectrum of patients who stand to benefit from ArtFun+: “Our patient population encompasses three main categories. Firstly, those with aortic diseases, such as aortic aneurysms, where early visualization and prediction are crucial. Secondly, patients with valvular pathologies, including leaks and stenosis, stand to gain from this technology.”
He continues, “Additionally, ArtFun+ aids in predicting the evolution of patients without an immediate need for diagnosis. For instance, we use aortic elasticity as a potent early marker for potential cardiovascular events. We’ve even uncovered its significance in young patients with infarctions as a predictive biomarker for relapse. For coronary disease and ischemic cardiomyopathies, we conduct not only diagnostic MRIs but also prognostic evaluations to assess the risk of relapse.”
Question 4: A Paradigm Shift in Imaging and Patient Care
Dr. Alban Redheuil concludes with an innovative perspective: “ArtFun+ introduces a transformative shift in medical imaging. It’s not merely an illustrative tool; it’s a highly precise diagnostic solution and a soon-to-be prognosis tool. This technology not only enhances short-term diagnoses but also empowers us to offer long-term prognostic insights that have the potential to reshape patient care.”
What are the benefits of a close collaboration between Imageens and Pitié-Salpêtrière?
The goal is to accelerate patient access to cutting-edge technologies
About Imageens:
Imageens is a Paris-based Healthtech company founded in 2017, focusing on the prevention and early diagnosis of cardiovascular diseases (CVD). Since its inception, Imageens has been immersed in international DeepTech and established with the goal of developing market-ready medical image processing software based on over 10 years of technical and clinical research conducted by world-class research institutions such as Sorbonne Université, the AP-HP, and Johns Hopkins.
From the outset, Imageens has demonstrated its capability to harness advanced AI in creating cutting-edge medical software. This innovation has earned recognition through several prestigious French innovation competitions and multiple innovation labels.
Today, Imageens leads the charge in the rapidly growing field of AI in cardiovascular health and medical imaging. The company possesses the world’s most clinically validated technology for analyzing arterial function through MRI, deploying this technology alongside other AI components to revolutionize treatment decisions in cardiovascular health and beyond. www.imageens.com.
About Pitié-Salpêtrière Hospital:
The Pitié Salpêtrière University Hospital is a public health establishment that is part of the Assistance Publique – Hôpitaux de Paris (AP-HP).
A local and specialist hospital for teaching and research, the Pitié Salpêtrière hospital is, by its size, the leading French hospital group.
Located in the heart of the 13th arrondissement of Paris, it brings together, within 90 buildings spread over 33 hectares, 77 services grouped into 10 centers representing all existing medical activities.
